{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:04:51Z","timestamp":1768568691080,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12185-023-03550-w","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T07:17:14Z","timestamp":1676618234000},"page":"900-909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma"],"prefix":"10.1007","volume":"117","author":[{"given":"Tomotaka","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-1279","authenticated-orcid":false,"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Kamezaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Nishitarumizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimi","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Marumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Oiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asahi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Ri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Aritsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"3550_CR1","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412\u201323.","journal-title":"N Engl J Med"},{"key":"3550_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403\u201316.","journal-title":"N Engl J Med"},{"key":"3550_CR3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","volume":"397","author":"A Fontanet","year":"2021","unstructured":"Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet. 2021;397:952\u20134.","journal-title":"Lancet"},{"key":"3550_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069761","volume":"376","author":"AS Lauring","year":"2022","unstructured":"Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T. Clinical severity of, and effectiveness of mRNA vaccines against, Covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376: e069761.","journal-title":"BMJ"},{"key":"3550_CR5","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1182\/blood.2021013768","volume":"139","author":"M Mittelman","year":"2022","unstructured":"Mittelman M, Magen O, Barda N, Dagan N, Oster HS, Leader A, et al. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 2022;139:1439\u201351.","journal-title":"Blood"},{"key":"3550_CR6","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165\u201373.","journal-title":"Blood"},{"key":"3550_CR7","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/bloodadvances.2021006302","volume":"6","author":"A Okamoto","year":"2022","unstructured":"Okamoto A, Fujigaki H, Iriyama C, Goto N, Yamamoto H, Mihara K, et al. CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv. 2022;6:3230\u20133.","journal-title":"Blood Adv"},{"key":"3550_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.2021012443","volume":"138","author":"P Ghione","year":"2021","unstructured":"Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. Blood. 2021;138:811\u20134.","journal-title":"Blood"},{"key":"3550_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","volume":"39","author":"LM Greenberger","year":"2021","unstructured":"Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031\u20133.","journal-title":"Cancer Cell"},{"key":"3550_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2021.2159","volume":"7","author":"S Yazaki","year":"2021","unstructured":"Yazaki S, Yoshida T, Kojima Y, Yagishita S, Nakahama H, Okinaka K, et al. Difference in SARS-CoV-2 antibody status between patients with cancer and health care workers during the COVID-19 pandemic in Japan. JAMA Oncol. 2021;7:1141\u20138.","journal-title":"JAMA Oncol"},{"key":"3550_CR11","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1038\/s41598-021-84387-3","volume":"11","author":"K Noda","year":"2021","unstructured":"Noda K, Matsuda K, Yagishita S, Maeda K, Akiyama Y, Terada-Hirashima J, et al. A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Sci Rep. 2021;11:5198.","journal-title":"Sci Rep"},{"key":"3550_CR12","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/bloodadvances.2021006917","volume":"6","author":"S Haggenburg","year":"2022","unstructured":"Haggenburg S, Lissenberg-Witte BI, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, et al. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Adv. 2022;6:1537\u201346.","journal-title":"Blood Adv"},{"key":"3550_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/TP.0000000000003983","volume":"106","author":"JF Sanders","year":"2022","unstructured":"Sanders JF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106:821\u201334.","journal-title":"Transplantation"},{"key":"3550_CR14","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","volume":"22","author":"SF Oosting","year":"2021","unstructured":"Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AC, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021;22:1681\u201391.","journal-title":"Lancet Oncol"},{"key":"3550_CR15","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1001\/jama.2021.15125","volume":"326","author":"D Steensels","year":"2021","unstructured":"Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326:1533\u20135.","journal-title":"JAMA"},{"key":"3550_CR16","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","volume":"27","author":"P Tang","year":"2021","unstructured":"Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27:2136\u201343.","journal-title":"Nat Med"},{"key":"3550_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2115463","volume":"386","author":"BA Dickerman","year":"2022","unstructured":"Dickerman BA, Gerlovin H, Madenci AL, Kurgansky KE, Ferolito BR, Figueroa Mu\u00f1iz MJ, et al. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in US veterans. N Engl J Med. 2022;386:105\u201315.","journal-title":"N Engl J Med"},{"key":"3550_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1182\/blood.2021013445","volume":"139","author":"N Liebers","year":"2022","unstructured":"Liebers N, Speer C, Benning L, Bruch PM, Kraemer I, Meissner J, et al. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood. 2022;139:142\u20137.","journal-title":"Blood"},{"key":"3550_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s12185-022-03305-z","volume":"115","author":"K Narita","year":"2022","unstructured":"Narita K, Nakaji S, Tabata R, Terao T, Kuzume A, Tsushima T, et al. Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol. 2022;115:728\u201336.","journal-title":"Int J Hematol"},{"key":"3550_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149150","author":"A Mazzoni","year":"2021","unstructured":"Mazzoni A, Di Lauria N, Maggi L, Salvati L, Vanni A, Capone M, et al. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J Clin Invest. 2021;131:e149150\u00a0","journal-title":"J Clin Invest"},{"key":"3550_CR21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","volume":"22","author":"L Monin","year":"2021","unstructured":"Monin L, Laing AG, Mu\u00f1oz-Ruiz M, McKenzie DR, Barrio DMD, I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765\u201378.","journal-title":"Lancet Oncol"},{"key":"3550_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.immuni.2021.01.014","volume":"54","author":"I Quast","year":"2021","unstructured":"Quast I, Tarlinton D. B cell memory: understanding COVID-19. Immunity. 2021;54:205\u201310.","journal-title":"Immunity"},{"key":"3550_CR23","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s10875-022-01325-2","volume":"42","author":"G Lamacchia","year":"2022","unstructured":"Lamacchia G, Mazzoni A, Spinicci M, Vanni A, Salvati L, Peruzzi B, et al. Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalization. J Clin Immunol. 2022;42:1379\u201391.","journal-title":"J Clin Immunol."},{"key":"3550_CR24","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1016\/j.vaccine.2022.03.057","volume":"40","author":"H Kato","year":"2022","unstructured":"Kato H, Miyakawa K, Ohtake N, Yamaoka Y, Yajima S, Yamazaki E, et al. Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination. Vaccine. 2022;40:2652\u20135.","journal-title":"Vaccine"},{"key":"3550_CR25","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386:2188\u2013200.","journal-title":"N Engl J Med"},{"key":"3550_CR26","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941\u201350.","journal-title":"N Engl J Med"},{"key":"3550_CR27","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397\u2013408.","journal-title":"N Engl J Med"},{"key":"3550_CR28","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2022","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19\u2014final report. N Engl J Med. 2022;383:1813\u201326.","journal-title":"N Engl J Med"},{"key":"3550_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41467-022-28578-0","volume":"13","author":"D Re","year":"2022","unstructured":"Re D, Seitz-Polski B, Brglez V, Carles M, Gra\u00e7a D, Benzaken S, et al. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Nat Commun. 2022;13:864.","journal-title":"Nat Commun"},{"key":"3550_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100631","volume":"3","author":"T Takano","year":"2022","unstructured":"Takano T, Morikawa M, Adachi Y, Kabasawa K, Sax N, Moriyama S, et al. Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine. Cell Rep Med. 2022;3: 100631.","journal-title":"Cell Rep Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03550-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03550-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03550-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T12:03:23Z","timestamp":1685275403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03550-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3550"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03550-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"13 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Iida reports research funding and consulting fees from Pfizer. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the Nagoya City University Hospital and was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants to store their blood samples.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}